CA2239780C - Procede pour reguler le tonus vagal - Google Patents

Procede pour reguler le tonus vagal Download PDF

Info

Publication number
CA2239780C
CA2239780C CA002239780A CA2239780A CA2239780C CA 2239780 C CA2239780 C CA 2239780C CA 002239780 A CA002239780 A CA 002239780A CA 2239780 A CA2239780 A CA 2239780A CA 2239780 C CA2239780 C CA 2239780C
Authority
CA
Canada
Prior art keywords
vagal
atp
antagonist
tone
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002239780A
Other languages
English (en)
Other versions
CA2239780A1 (fr
Inventor
Amir Pelleg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/771,518 external-priority patent/US5874420A/en
Application filed by Duska Scientific Co filed Critical Duska Scientific Co
Publication of CA2239780A1 publication Critical patent/CA2239780A1/fr
Application granted granted Critical
Publication of CA2239780C publication Critical patent/CA2239780C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés pour modifier la tonus vagal chez un patient, en lui administrant une quantité suffisante, pour avoir un effet thérapeutique, d'un médiateur des purinorécepteurs P2x situés sur les terminaisons afférentes du nerf vague. L'invention concerne également des utilisations diagnostiques.
CA002239780A 1995-12-26 1996-12-24 Procede pour reguler le tonus vagal Expired - Fee Related CA2239780C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US922895P 1995-12-26 1995-12-26
US60/009,228 1995-12-26
US08/771,518 US5874420A (en) 1995-12-26 1996-12-23 Process for regulating vagal tone
US08/771,518 1996-12-23
PCT/US1996/020255 WO1997023218A1 (fr) 1995-12-26 1996-12-24 Procede pour reguler le tonus vagal

Publications (2)

Publication Number Publication Date
CA2239780A1 CA2239780A1 (fr) 1997-07-03
CA2239780C true CA2239780C (fr) 2008-08-26

Family

ID=39717687

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002239780A Expired - Fee Related CA2239780C (fr) 1995-12-26 1996-12-24 Procede pour reguler le tonus vagal

Country Status (1)

Country Link
CA (1) CA2239780C (fr)

Also Published As

Publication number Publication date
CA2239780A1 (fr) 1997-07-03

Similar Documents

Publication Publication Date Title
US5874420A (en) Process for regulating vagal tone
JP3836128B2 (ja) プリン組成物および投与方法
US5573772A (en) Methods for protecting tissues and organs from ischemic damage
US4673563A (en) Adenosine in the treatment of supraventricular tachycardia
Aubier et al. Diaphragmatic contractility enhanced by aminophylline: role of extracellular calcium
Pelleg et al. Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals.
US4364922A (en) Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
AU739275B2 (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
Lee et al. Electromyographic and mechanomyographic characteristics of neuromuscular block by magnesium sulphate in the pig.
DE69821498T2 (de) Verwendung von amifostin
CA2239780C (fr) Procede pour reguler le tonus vagal
WO2014134419A1 (fr) Utilisation de bloqueurs ikach pour le traitement de maladies cardiaques
US6924272B2 (en) Medicinal composition for diabetic neuropathy
FERRARI et al. Modification of the baroreceptor control of atrio-ventricular conduction induced by digitalis in man
Ravi et al. Role of vagal lung C-fibres in the cardiorespiratory effects of capsaicin in monkeys
Hiasa et al. Three elderly cases with Brugada-type electrocardiographic pattern unmasked by pilsicainide at the toxic level
JP2000026295A (ja) 虚血再潅流損傷の治療薬ならび不整脈および心筋梗塞による心不全を含む細胞機能障害の治療薬
WO2019131308A1 (fr) TRAITEMENT D'UNE ARYTHMIE EN FAISANT APPEL À LA 9-β-D-ARABINOFURANOSYLHYPOXANTINE
RU2493836C1 (ru) Фармацевтическая комбинация для профилактики и лечения хронических нарушений вегетативной регуляции ритма сердца и способ профилактики и лечения с помощью фармацевтической комбинации
Olgart et al. Inhibition of compound 48/80‐induced intradental sensory nerve activity by disodium cromoglycate and serotonin antagonists
RU2248208C2 (ru) Пуринрибозиды в качестве антиаритмических средств
Dobmeyer et al. Antiarrhythmic effects of flecainide against canine ventricular arrhythmias induced by two-stage coronary ligation and halothane-epinephrine
Seidl et al. Electrophysiological effects of ULFS 49 CL

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20121224